Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Inflammation AND Rheumatoid Arthritis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    143 result(s) found for: Inflammation AND Rheumatoid Arthritis. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2010-023469-22 Sponsor Protocol Number: P10.YYY/ APCP-107 Start Date*: 2011-03-09
    Sponsor Name:LUMC
    Full Title: A phase II study of ARA 290 as therapeutic strategy in rheumatoid arthritis
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039073 Rheumatoid arthritis LLT
    12.1 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000491-16 Sponsor Protocol Number: CACZ885A2201E1 Start Date*: 2007-04-30
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: Estudio de extensión abierto de 76 semanas de duración para evaluar la eficacia, seguridad y tolerabilidad de ACZ885 (anticuerpo monoclonal anti-interleuquina-1β) en pacientes con artritis reumatoi...
    Medical condition: Artritis Reumatoide
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Prematurely Ended) AT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000760-24 Sponsor Protocol Number: ACT5488 Start Date*: 2007-06-21
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: Activity and safety of oral administration of SSR150106XB for the reduction of inflammation in patients with active rheumatoid arthritis (RA): A 4-week, multi-center, randomized, double-blind, plac...
    Medical condition: Patients with active rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-001665-15 Sponsor Protocol Number: CACZ885A2211 Start Date*: 2007-09-14
    Sponsor Name:Novartis Farmaceutica S.A.
    Full Title: Estudio de extensión abierto, multicéntrico, de fase II, de 54 semanas de duración, para evaluar la eficacia, seguridad y tolerabilidad de ACZ885 (anticuerpo monoclonal anti-interleuquina-1β) en pa...
    Medical condition: Artritis Reumatoide
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Prematurely Ended) BE (Completed) IT (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005287-21 Sponsor Protocol Number: Simon1234 Start Date*: 2023-06-01
    Sponsor Name:Rigshospitalet, Center for Aktiv Sundhed, section 7641
    Full Title: Exercise-induced cardiac adaptions in rheumatoid arthritis patients during interleukin-6 vs. tumor necrosis factor antibody therapy: a randomised controlled study (RABEX).
    Medical condition: Rheumatoid Athritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004859 10003268 Arthritis rheumatoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-024516-34 Sponsor Protocol Number: CAIN457F2206 Start Date*: 2011-08-31
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, placebo-controlled regimen finding study of efficacy, safety and tolerability of secukinumab at 12 weeks administered with an i.v. or s.c. loading regimen compared to pl...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) IT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2013-001492-20 Sponsor Protocol Number: NN8226-4064 Start Date*: 2014-02-12
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised, active comparator, double-blind, multi centre, parallel, phase 2a trial, investigating the mechanism of action of NNC0109-0012 (anti-IL-20 mAb) through synovial biopsies in subjects w...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002908-15 Sponsor Protocol Number: RR-152-REDO Start Date*: 2016-11-08
    Sponsor Name:Sint Maartenskliniek
    Full Title: REDO study: RhEumatoid arthritis REtreatment with ultra-low dose Rituximab: Disease Outcome after Dose Optimization
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-006562-20 Sponsor Protocol Number: JAKIPRA Start Date*: 2022-10-26
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: JAK Inhibition in PReclinical Arthritis
    Medical condition: Preclinical Phase of rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-011268-13 Sponsor Protocol Number: RN08RH469 Start Date*: 2009-12-31
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: Optimal management of rheumatoid arthritis patients who require biologic therapy (ORBIT study)
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-001625-10 Sponsor Protocol Number: 0881X1-4437 Start Date*: 2008-06-16
    Sponsor Name:Wyeth Pharmaceuticals France
    Full Title: An Open-Label, Randomized Study To Evaluate The Radiographic Efficacy And Safety Of Enbrel™ (Etanercept) Added To Methotrexate In Comparison With Usual Treatment In Subjects With Moderate Rheumatoi...
    Medical condition: RHEUMATOID ARTHRITIS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) ES (Completed) GB (Prematurely Ended) DE (Prematurely Ended) FR (Completed) CZ (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended) DK (Completed) IE (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002645-37 Sponsor Protocol Number: KC706-C05 Start Date*: 2006-08-25
    Sponsor Name:Kémia, Inc.
    Full Title: A Phase II randomized double-blind placebo-controlled Study of KC706 in patients with rheumatoid arthritis inadequately controlled with a stable dose of methotrexate
    Medical condition: Active rheumatoid arthritis (RA), patients taking stable doses of methotrexate
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006021-23 Sponsor Protocol Number: 015K-CL-RA25 Start Date*: 2013-01-04
    Sponsor Name:Astellas Pharma Global Development
    Full Title: A Phase 2, Open-Label, Non-Comparative, Multi-Center Extension Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthrit...
    Medical condition: Rheumatoid arthritis (RA) is a chronic systemic inflammatory autoimmune disease that targets the synovial tissues [O’Dell, 2004]. The synovial inflammation may cause irreversible cartilage destruct...
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004859 10042952 Systemic rheumatoid arthritis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) CZ (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-005096-12 Sponsor Protocol Number: OPRERA Start Date*: 2021-05-31
    Sponsor Name:Karolinska Universitetssjukhuset
    Full Title: Utvärdering av två kortison behandlingsstrategier hos patienter med nydiagnostiserad, tidigare obehandlad reumatoid artrit: en randomiserad, öppen, non-inferiority klinisk studie
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000089-72 Sponsor Protocol Number: 204 Start Date*: 2015-03-26
    Sponsor Name:Policlinico Gemelli-CIC- UCSC
    Full Title: FAT GENE EXPRESSION IN OVERWEIGHT AND OBESE PATIENTS WITH PERSISTENTLY ACTIVE RHEUMATOID ARTHRITIS TREATED WITH ABATACEPT AND CLINICAL RESPONSE
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002341-11 Sponsor Protocol Number: WA29049 Start Date*: 2013-10-25
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A SINGLE BLIND PHASE IV PHARMACODYNAMIC STUDY TO EVALUATE NEUTROPHIL DISTRIBUTION KINETICS AND FUNCTION FOLLOWING SINGLE-DOSE TOCILIZUMAB TREATMENT IN HEALTHY SUBJECTS
    Medical condition: healthy volunteers (intended indication: Rheumatoid Arthritis)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022378-15 Sponsor Protocol Number: VT-4001-001-SP Start Date*: 2011-05-25
    Sponsor Name:Nycomed GmbH
    Full Title: VELVET (Veltuzumab various doses exploratory trial), a randomized, double blind, placebo controlled, multicentre, multinational phase II dose range finding trial in subjects with moderate to severe...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005320-81 Sponsor Protocol Number: CACZ885A2201E2 Start Date*: 2008-10-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 2-year open-label second extension study to evaluate the safety, tolerability and efficacy of canakinumab (ACZ885) an anti-interleukin-1β monoclonal antibody in patients with active rheumatoid ar...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000609-58 Sponsor Protocol Number: NN8226-3612 Start Date*: 2013-02-20
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoi...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Prematurely Ended) GB (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-002846-36 Sponsor Protocol Number: A3921019 Start Date*: 2005-06-14
    Sponsor Name:Pfizer Pharma GmbH
    Full Title: A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO COMPARE 3 DOSE LEVELS OF CP 690,550 VERSUS PLACEBO, ADMINISTERED ORALLY TWICE DAILY (BID) FOR 6 WEEKS, IN THE TREATME...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    7.1 10039073 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) SK (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 08 07:23:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA